Overview

A Study of 2 Doses of MAP0010 in Asthmatic Children

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Treatments:
Budesonide